ImmunoGen, Inc. (IMGN)
(Delayed Data from NSDQ)
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.88 USD
+0.38 (15.20%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.93 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
New Strong Buy Stocks for October 20th
by Zacks Equity Research
OSCR, IMGN, AFRM, ACVA and SOLO have been added to the Zacks Rank #1 (Strong Buy) List on October 20, 2023.
New Strong Buy Stocks for October 18th
by Zacks Equity Research
MRO, APA, IMGN, RAIL and MFA have been added to the Zacks Rank #1 (Strong Buy) List on October 18, 2023.
3 Solid Stocks to Buy for Superb Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks such as Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN) and Inari Medical (NARI) for solid earnings acceleration.
4 Stocks That Exhibit Solid Earnings Acceleration
by Tirthankar Chakraborty
Invest in stocks like Catalyst Pharmaceuticals (CPRX), ImmunoGen (IMGN), Inari Medical (NARI) and Kyndryl Holdings (KD) for superb earnings acceleration.
Wall Street Analysts Think ImmunoGen (IMGN) Could Surge 49.11%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for ImmunoGen (IMGN) points to a 49.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Is Catalyst (CPRX) Down 14% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Emergent (EBS) reports wider-than-expected second-quarter loss. The company lowered its 2023 guidance for some products and services.
Amicus (FOLD) Misses on Q2 Earnings, Raises Revenue Guidance
by Zacks Equity Research
Amicus (FOLD) incurs wider-than-expected loss in the second quarter. Fabry disease drug Galafold reports encouraging revenues and the company raises its 2023 guidance for the same.
Theravance's (TBPH) Q2 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Thervance's (TBPH) second-quarter 2023 loss is narrower than expected. Revenues rise year over year.
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.
Intellia (NTLA) Misses on Q2 Earnings, Gives Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) second-quarter earnings miss estimates. The company provides an update on its gene-editing pipeline.
Agios (AGIO) Q2 Earnings Beat Estimates, Revenues In Line
by Zacks Equity Research
Agios (AGIO) reports narrower-than-expected loss in the second quarter of 2023. The revenues are in line with the Zacks Consensus Estimate.
Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View
by Zacks Equity Research
Corcept's (CORT) second-quarter earnings and revenues beat estimates. The company gives updates on its pipelines and raises revenue guidance for 2023, reflecting strong performance of Korlym.
Amarin (AMRN) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amarin's (AMRN) second-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance
by Zacks Equity Research
Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.
Esperion (ESPR) Q2 Earnings Top, Stock Up on Strong Revenues
by Zacks Equity Research
Esperion's (ESPR) second-quarter earnings and revenues beat estimates. The stock surged 7.64% on Tuesday.
ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
ImmunoGen's (IMGN) Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. The company, however, did not issue any product sales guidance for Elahere for 2023.
Best Momentum Stocks to Buy for August 1st
by Zacks Equity Research
UAL, BJRI and IMGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 1, 2023.
ImmunoGen (IMGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of 87.50% and 94.09%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ImmunoGen (IMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
ImmunoGen (IMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
by Zacks Equity Research
Here is how ANI Pharmaceuticals (ANIP) and ImmunoGen (IMGN) have performed compared to their sector so far this year.
ImmunoGen (IMGN) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?